ArticleAmerican journal of surgery2020
Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database.
Article in American journal of surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Best treatment options for occult breast cancer: A meta-analysis.Frontiers in oncology · 2023Pooled it
- Is Mastectomy Necessary in Patients with Occult Breast Cancer and Advanced (N2/N3) Nodal Disease?Annals of surgical oncology · 2026Observational
- Overall survival outcomes in occult primary breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- Occult Breast Carcinoma: Pathologic Features of an Uncommon Clinical Presentation in a Large Cohort.The American journal of surgical pathology · 2026Article
- Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.Breast cancer (Tokyo, Japan) · 2025Review
- Occult breast cancer in an older woman: A case report.Experimental and therapeutic medicine · 2025Article
- Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer.The American journal of case reports · 2024Article
- Clinicopathological features, psychological status, and prognosis of 33 patients with occult breast cancer.World journal of psychiatry · 2024Article
- Prognostic Models Using Machine Learning Algorithms and Treatment Outcomes of Occult Breast Cancer Patients.Journal of clinical medicine · 2023Article
- Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study.BMC surgery · 2022Article
- De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.Current breast cancer reports · 2022Review
- De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.European journal of breast health · 2022Review
- Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundControversy exists regarding optimal treatment of occult breast cancer (OBC). Treatment options include mastectomy alone (MAST), radiation alone (XRT), or mastectomy with radiation (MXRT).
methodsWe queried the National Cancer Database from 2004 to 2014 for patients with OBC who underwent MAST, XRT, or MXRT. We utilized propensity score matching to perform three head-to-head comparisons. Kaplan-Meier analysis was performed to compare overall survival (OS).
resultsA total of 190 patients received XRT, 237 received MAST, and 244 received MXRT. In the MXRT vs. XRT comparison, 5-year OS was 78.2% and 82.8%, respectively. In the MXRT vs. MAST comparison, 5-year OS was 81.5% and 86.7%, respectively. In the MAST vs. XRT comparison, 5-year OS was 83.2% and 82.5%, respectively. There was no difference in OS for all paired comparisons.
conclusionsThere were no OS differences in patients undergoing MAST, XRT, or MXRT, suggesting that breast conservation can be considered in patients with OBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.